x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001108
| Product Information | |
|---|---|
| Product Name | Human GLP-1 (7-36) ELISA Kit, Fluorescent |
| Species | Human; Sheep; Horse; Cow; Pig |
| Description | GLP-1 (7-36) in vitro CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of GLP-1 (7-36) protein in human serum, plasma, and cell culture supernatants. |
| Sample Types | Cell Culture Supernatant, Serum, Hep Plasma, Cit Plasma |
| Detection Range | 14.6 pg/mL - 1000 pg/mL |
| Sensitivity | 12 pg/mL |
| Target Information | |
|---|---|
| Target Name | GCG |
| UniProt No. | P01275 |
| Gene ID | 2641 |
| Target Description | Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferaton. Inhibits beta cell apoptosis.GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. |
| Alternative Names | GCG; Glicentin related polypeptide; glicentin-related polypeptide; GLP-1; GLP-1(7-36); GLP-1(7-37); GLP-2; GLP1; GLP1, included; GLP2; GLP2, included; GLUC_HUMAN; Glucagon; Glucagon like peptide 1; glucagon-like peptide 1; Glucagon-like peptide 1, included; Glucagon-like peptide 2; Glucagon-like peptide 2, included; GRPP; OXM; OXY; preproglucagon |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
